Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or resistance. While generally well tolerated, das...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Timothy P., Laneuville, Pierre, Rousselot, Philippe, Snyder, David S., Rea, Delphine, Shah, Neil P., Paar, David, Abruzzese, Elisabetta, Hochhaus, Andreas, Lipton, Jeffrey H., Cortes, Jorge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312029/
https://www.ncbi.nlm.nih.gov/pubmed/30093398
http://dx.doi.org/10.3324/haematol.2018.188987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312029/
https://www.ncbi.nlm.nih.gov/pubmed/30093398
http://dx.doi.org/10.3324/haematol.2018.188987

Ejemplares similares